Clinical Trial Update: A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind, placebo-controlled trial is evaluating fampridine for spinocerebellar ataxia type 27B due to an FGF14 gene expansion. Recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinocerebellar Ataxia Type 27b

Drugs mentioned

• Fampridine (4-aminopyridine)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Spinocerebellar Ataxia 27B (SCA27B) | Phase 3 | Status: RECRUITING